Company Analysis Gland Pharma Limited
1. Summary
Disadvantages
- Price (1689.7 βΉ) is higher than fair price (540.46 βΉ)
- Dividends (1.07%) are below the sector average (9.06%).
- The stock's return over the last year (-9.8%) is lower than the sector average (0%).
- Current debt level 3.49% has increased over 5 years from 0.1584%.
- The company's current efficiency (ROE=9.26%) is lower than the sector average (ROE=10.54%)
Similar companies
2. Share price and performance
2.1. Share price
2.3. Market efficiency
Gland Pharma Limited | Healthcare | Index | |
---|---|---|---|
7 days | 2.5% | 3.4% | 0.2% |
90 days | 21.3% | 14.5% | 3.9% |
1 year | -9.8% | 0% | 2.9% |
GLAND vs Sector: Gland Pharma Limited has significantly underperformed the "Healthcare" sector by -9.8% over the past year.
GLAND vs Market: Gland Pharma Limited has significantly underperformed the market by -12.66% over the past year.
Stable price: GLAND is not significantly more volatile than the rest of the market on "National Stock Exchange Of India" over the last 3 months, with typical variations of +/- 5% per week.
Long period: GLAND with weekly volatility of -0.1885% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (1689.7 βΉ) is higher than the fair price (540.46 βΉ).
Price is higher than fair: The current price (1689.7 βΉ) is 68% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (39.35) is lower than that of the sector as a whole (59.52).
P/E vs Market: The company's P/E (39.35) is lower than that of the market as a whole (66.04).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (3.48) is lower than that of the sector as a whole (6.59).
P/BV vs Market: The company's P/BV (3.48) is lower than that of the market as a whole (6.6).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (5.39) is lower than that of the sector as a whole (9.3).
P/S vs Market: The company's P/S indicator (5.39) is lower than that of the market as a whole (18.95).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (20.23) is lower than that of the sector as a whole (141.59).
EV/Ebitda vs Market: The company's EV/Ebitda (20.23) is lower than that of the market as a whole (24.96).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -0.0103% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-0.0103%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-3.49%).
5.4. ROE
ROE vs Sector: The company's ROE (9.26%) is lower than that of the sector as a whole (10.54%).
ROE vs Market: The company's ROE (9.26%) is higher than that of the market as a whole (3.54%).
5.5. ROA
ROA vs Sector: The company's ROA (7.95%) is higher than that of the sector as a whole (7.51%).
ROA vs Market: The company's ROA (7.95%) is higher than that of the market as a whole (7.89%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (16.06%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (15.45%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 1.07% is below the average for the sector '9.06%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 1.07% has been steadily paid over the past 7 years, DSI=1.
Weak dividend growth: The company's dividend yield 1.07% has been growing weakly or stagnant over the past 5 years. Growth over only 1 year.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription